Presentations and Posters
Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy
Toshinari Yamashita, Norikazu Masuda, Naohito Yamamoto, Naoto Kondo, Hiroko Bando, Sayuri Akiyoshi, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Tomomi Fujisawa, Hiroshi Ishiguro, Hirotaka Nakayama, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Hiroyuki Yasojima, Hiroi Kasai, Tastuki R. Kataoka, Satoshi Morita, Masakazu Toi
ECCO, 2015 Sep, Wien Austria (Poster)
Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients (pts)
Hiroko Bando, Norikazu Masuda, Rikiya Nakamura, Naoto Kondo, Katsumasa Kuroi, Mayumi Ishida, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Yasuhiro Yanagita, Hiroshi Ishiguro, Satoru Shimizu, Kenjiro Aogi, Sadao Amano, Shinji Ozaki, Akiko Iguchi-Manaka, Hiroi Kasai, Satoshi Morita, Tastuki R. Kataoka, Masakazu Toi
ECCO, 2015 Sep, Wien Austria (Poster)
Bevacizumab plus Paclitaxel optimization study with interventional maintenance endocrine therapyin advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial
Shigehira Saji, Masakazu Toi, Takashi Ishikawa, Takanori Ishida, Shoichiro Ohtani, Masahiro Kashiwaba,Yasuaki Sagara, Shigenori Nagai, Yoshie Hasegawa, Tomomi Fujisawa, Norikazu Masuda, Koji Matsumoto,Yutaka Yamamoto, Hiroshi Yoshibayashi, Naruto Taira, Satoshi Morita, Shinji Ohno
2014 ASCO Poster (trial in progress)
Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer
Hiroji Iwata, Naohito Yamamoto, Norikazu Masuda, Hiroko Bando, Katsumasa Kuroi, Shinji Ohno, Hiroi Kasai, Satoshi Morita, Takaki Sakurai, Masakazu Toi
St.Gallen Poster
Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: a multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katsumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yasuhiro Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita, Masakazu Toi
2013 SABCS Poster
A randomized study of docetaxel + cyclophosphamide (TC), 5-fluorouracil + epirubicin + cyclophosphamide (FEC)-TC, and TC-FEC as preoperative chemotherapy for hormone receptor-positive and HER2-negative primary breast cancer: Japan Breast Cancer Research Group (JBCRG) – 09
Nobuaki Sato, Norikazu Masuda, Kenji Higaki, Takashi Morimoto, Yasuhiro Yanagita, Makiko Mizutani, Shoichiro Ohtani, Koji Kaneko, Tomomi Fujisawa, Masato Takahashi, Takayuki Kadoya, Nobuki Matsunami, Yutaka Yamamoto, Shinji Ohno, Toshimi Takano, Satoshi Morita, Sachiko Tanaka, and Masakazu Toi
2013 SABCS Poster
Safety of trastuzumab in HER2 positive primary breast cancer in Japan; Initial safety report for the large scale cohort study (JBCRG-C01)
Naohito Yamamoto, Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, Shoichiro Ohtani, Masato Takahashi, Kosuke Yamazaki, Makoto Kato, Shinji Ohno, Katumasa Kuroi, Kazuhiko Yamagami, Takashi Morimoto, Yoshie Hasegawa, Toshimi Takano, Takayuki Kadoya, Mitsuchika Hosoda, Hajime Abe, Satoshi Morita, Shinji Yasuno, Masakazu Toi
2013 ASCO Poster
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (JBCRG-13)
Kenji Higaki, Norikazu Masuda, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani,Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
2013 ASCO Poster
Cohort study evaluating trastuzumab in HER2 positive early breast cancer in Japan; JBCRG-C01
Norikazu Masuda, Hiroyasu Yamashiro, Hiroji Iwata, Reiki Nishimura, Nobuaki Sato, Takako Kamio, T. Saito, Tecchuu Lee, Shinji Yasuno, Masakazu Toi
St Gallen 2013, 3
Inter-observer concordance of Ki-67 labeling index inbreast cancer[br]: Japan Breast Cancer Research Group (JBCRG) Ki-67 Ring Study
Takayuki Ueno, Yoshiki Mikami, Kenichi Yoshimura, Hitoshi Tsuda, Masafumi Kurosumi, Shinobu Masuda, Rie Horii, Masakazu Toi, and Hironobu Sasano
2012 SABCS Poster Session 5
by Voluntary Organization JBCRG